Warning
Merck Sharp & Dohme LLC Recalls Noxafil Powdermix (posaconazole) for Delayed-Release Oral
This is a Class II recall. This product may cause temporary health problems or pose a slight threat of a serious nature.
Source: FDA
WarningRecall #D-0242-2026Drug / Pharmaceutical
Merck Sharp & Dohme LLC Recalls Noxafil Powdermix (posaconazole) for Delayed-Release Oral
Merck Sharp & Dohme LLC · Class II — Moderate Risk
Product Description
Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway, NJ 07056 USA, Manufactured by: N.V. Organon, 5349 AB Oss, The Netherlands, a subsidiary of Organon & Co., Jersey City, NJ 07302, USA NDC 0085-2224-02.
Reason for Recall
Presence of particulate matter: potential presence of metal particulates in the product.
FDA Classification
Class II — Moderate Risk
A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Distribution
Nationwide in the USA
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Merck Sharp & Dohme LLC has recalled a pharmaceutical product that the FDA classified as Class II affecting 845 kits. The recall was initiated on December 12, 2025. Presence of particulate matter: potential presence of metal particulates in the product. It was distributed nationwide. Class II recalls involve products that might cause a temporary health problem or pose only a slight threat of a serious nature. Consumers should discontinue use and contact the firm.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination.